AbbVie announced plans to invest $100 billion in U.S. research and development and manufacturing over the next decade. The company said this move aligns with the Trump administration’s efforts to strengthen the domestic biopharmaceutical sector.
As part of its commitment, AbbVie will reduce Medicaid drug prices and join the government’s upcoming direct-to-consumer TrumpRx platform. This participation will include offering drugs such as Humira, Synthroid, Combigan, and Alphagan.
In return for these actions, AbbVie has secured exemptions from tariffs and future price mandates. Other terms of the agreement between AbbVie and the Trump administration remain confidential.
“AbbVie is following President Trump’s call to action by reaching this agreement, allowing us to collectively move beyond policies that harm American innovation,” CEO Robert Michael said in a statement.
AbbVie's $100 billion investment surpasses those of other major pharmaceutical companies. Johnson & Johnson previously announced a total of $57 billion in U.S.-based investments earlier in 2025. J&J also reached an agreement with the Trump administration last week to participate in TrumpRx at discounted rates and build two more manufacturing facilities, though it did not disclose the full value of its deal. Like AbbVie, J&J’s products will be exempt from tariffs under its new pact.
AstraZeneca follows with a $50 billion investment package announced last year, which includes increasing reliance on U.S. operations with a goal for the domestic market to represent half of its global revenue by 2030. GSK and Takeda have each committed $30 billion over five years, while Eli Lilly pledged $27 billion beginning in February 2025; Lilly’s projects include major facilities in Alabama, Virginia, and Puerto Rico.
